CDK Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

CDK Inhibitors, Antagonists & Activators

Product Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDK11	CDK12	CDK13	CDK14	CDK16	CDK19	CDC	CLK	Purity
Palbociclib				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM												≥95.0%
Abemaciclib	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM									99.83%
Palbociclib monohydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM												≥95.0%
Dinaciclib	CDK1, IC₅₀: 3 nM	CDK2, IC₅₀: 1 nM			CDK5, IC₅₀: 1 nM				CDK9, IC₅₀: 4 nM									99.36%
Ribociclib				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM												99.93%
BSJ-4-116											CDK12, IC₅₀: 6 nM							99.62%
Manzamine A hydrochloride					CDK5, IC₅₀: 1.5 μM													99.29%
XY028-140				CDK4		CDK6												98.28%
Ro-3306	CDK1, Ki: 20 nM CDK1/cyclinB1, Ki: 35 nM CDK1/cyclin A, Ki: 110 nM	CDK2/cyclinE, Ki: 340 nM																98.54%
Abemaciclib methanesulfonate	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM									≥98.0%
THZ1							CDK7, IC₅₀: 3.2 nM											≥98.0%
THZ531							CDK7, IC₅₀: 8.5 μM		CDK9, IC₅₀: 10.5 μM		CDK12, IC₅₀: 158 nM	CDK13, IC₅₀: 69 nM						99.86%
AZD4573									CDK9, IC₅₀: 4 nM									99.90%
Seliciclib	cdc2/cyclin B, IC₅₀: 0.65 μM	cdk2/cyclin A, IC₅₀: 0.7 μM Cdk2/cyclin E2, IC₅₀: 0.7 μM			CDK5/p35, IC₅₀: 0.16 μM													≥98.0%
Flavopiridol	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM														99.72%
SR-4835											CDK12, IC₅₀: 99 nM CDK12, Kd: 98 nM	CDK13, Kd: 4.9 nM						98.46%
Palbociclib isethionate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM												99.99%
Simurosertib																Cdc7, IC₅₀: <0.3 nM		99.07%
Fadraciclib		CDK2							CDK9									99.78%
NVP-2									CDK9, IC₅₀: 0.5 nM									≥98.0%
Zotiraciclib		CDK2, IC₅₀: 13 nM																99.96%
SNS-032	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM		CDK4, IC₅₀: 925 nM			CDK7, IC₅₀: 62 nM		CDK9, IC₅₀: 4 nM									99.49%
OTS964 hydrochloride										CDK11B, Kd: 40 nM								99.32%
AZD-5438	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk4-cyclin D1, IC₅₀: 449 nM	cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM		cdk9-cyclin T, IC₅₀: 20 nM									99.55%
AT7519	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM									99.76%
YKL-5-124 TFA		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM									98.59%
Mevociclib							CDK7											99.27%
Samuraciclib hydrochloride	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM									99.98%
BSJ-03-123						CDK6												99.45%
GSK 3 Inhibitor IX	Cdk1/cyclin B, IC₅₀: 320 nM	cdk2/cyclin A, IC₅₀: 300 nM		Cdk4/cyclin D1, IC₅₀: 10 μM	CDK5/p35, IC₅₀: 80 nM													≥98.0%
THZ1 Hydrochloride							CDK7, IC₅₀: 3.2 nM											98.49%
Kenpaullone	Cdk1/cyclin B, IC₅₀: 0.4 μM	cdk2/cyclin A, IC₅₀: 0.68 μM CDK2/cyclinE, IC₅₀: 7.5 μM			CDK5/p35, IC₅₀: 0.85 μM													98.01%
Flavopiridol Hydrochloride	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM														≥95.0%
AUZ 454		CDK2(C118L/A144C), Kd: 9.7 nM CDK2(A144C), Kd: 15.4 nM CDK2(C118L), Kd: 18.6 nM CDK2(WT), Kd: 50 nM CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM																99.99%
XL413 hydrochloride																Cdc7, IC₅₀: 3.4 nM		99.82%
AS2863619								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM			≥98.0%
NG 52	cdc2-cyclin B, IC₅₀: 0.34 μM				Pho85p, IC₅₀: 2 nM													99.97%
(+)-BAY-1251152									CDK9/CycT1, IC₅₀: 3 nM									99.66%
CCT-251921								CDK8, IC₅₀: 2.3 nM							CDK19, IC₅₀: 2.6 nM			99.77%
Wogonin								CDK8										99.98%
MBQ-167																Cdc42, IC₅₀: 78 nM		99.67%
BI-1347								CDK8, IC₅₀: 1.1 nM										99.83%
TG003																	CLK1, IC₅₀: 20 nM CLK2, IC₅₀: 200 nM CLK4, IC₅₀: 15 nM	99.62%
JNJ-7706621	Cdk1/cyclin B, IC₅₀: 9 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM	CDK3/Cyclin E, IC₅₀: 58 nM	Cdk4/cyclin D1, IC₅₀: 253 nM		CDK6/cyclinD1, IC₅₀: 175 nM												99.96%
KB-0742 dihydrochloride									CDK9/cyclinT1, IC₅₀: 6 nM									99.63%
CGP60474	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		CDK4/cyclin D, IC₅₀: 216 nM	Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM		CDK9/cycT, IC₅₀: 13 nM									98.70%
LDC4297							CDK7, IC₅₀: 0.13 nM											99.14%
SEL120-34A monohydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM			99.98%
BMS-265246	CDK1/cycB, IC₅₀: 6 nM	CDK2/Cyc E, IC₅₀: 9 nM		CDK4/cycD, IC₅₀: 230 nM														99.28%
Ribociclib succinate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM												99.52%
Senexin A								CDK8, Kd: 0.83 μM							CDK19, Kd: 0.31 μM			99.94%
Roniciclib	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM		CDK4/cyclin D, IC₅₀: 11 nM			CDK7/Cyclin H/MAT1, IC₅₀: 25 nM		CDK9/cyclinT1, IC₅₀: 5 nM									98.89%
Milciclib	cyclin B/CDK1, IC₅₀: 398 nM	cyclin A/CDK2, IC₅₀: 45 nM cyclin E/CDK2, IC₅₀: 363 nM		cyclin D1/CDK4, IC₅₀: 160 nM			cyclin H/CDK7, IC₅₀: 150 nM											99.89%
CVT-313	Cdk1/cyclin B, IC₅₀: 4.2 μM	cdk2/cyclin A, IC₅₀: 0.5 μM		Cdk4/cyclin D1, IC₅₀: 215 μM														99.76%
(R)-CR8 trihydrochloride	CDK1/cyclinB1, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM									99.02%
Ribociclib hydrochloride				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM												99.95%
CLK-IN-T3																	CLK1, IC₅₀: 0.67 nM CLK2, IC₅₀: 15 nM CLK3, IC₅₀: 110 nM	98.40%
CDK12-IN-3											CDK12, IC₅₀: 491 nM							98.22%
PHA-767491 hydrochloride	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM									99.91%
KH-CB19																	CLK1, IC₅₀: 19.7 nM CLK3, IC₅₀: 530 nM	99.66%
R547	Cdk1/cyclin B, Ki: 2 nM Cdk1/cyclin B, IC₅₀: 0.2 nM	CDK2/cyclinE, Ki: 3 nM cdk2/cyclin A, IC₅₀: 0.1 nM CDK2/cyclinE, IC₅₀: 0.4 nM	CDK3/Cyclin E, IC₅₀: 0.8 nM	CDK4/cyclin D, Ki: 1 nM	CDK5/p35, IC₅₀: 0.1 nM	cdk6/cyclin D3, IC₅₀: 4 nM	CDK7/cyclin H, IC₅₀: 171 nM											99.66%
THZ2	CDK1, IC₅₀: 96.9 nM	CDK2, IC₅₀: 222 nM			CDK5, IC₅₀: 134 nM		CDK7, IC₅₀: 13.9 nM	CDK8, IC₅₀: 6830 nM	CDK9, IC₅₀: 194 nM									≥95.0%
PHA-793887	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM		CDK9/cyclinT1, IC₅₀: 138 nM									99.25%
Trilaciclib hydrochloride				Cdk4/cyclin D1, IC₅₀: 1 nM		cdk6/cyclin D3, IC₅₀: 4 nM												99.24%
FN-1501		cdk2/cyclin A, IC₅₀: 2.47 nM		Cdk4/cyclin D1, IC₅₀: 0.85 nM		CDK6/cyclinD1, IC₅₀: 1.96 nM												99.71%
Atuveciclib	CDK1/CycB(h), IC₅₀: 1100 nM	CDK2/CycE(h), IC₅₀: 1000 nM	CDK3/CycE(h), IC₅₀: 890 nM		CDK5/p35(h), IC₅₀: 1600 nM				CDK9/CycT1, IC₅₀: 13 nM CDK9/CycT1(h), IC₅₀: 6 nM									99.20%
CDK2-IN-4	Cdk1/cyclin B, IC₅₀: 86 μM	cdk2/cyclin A, IC₅₀: 44 nM																≥97.0%
Purvalanol A	cdc2-cyclin B, IC₅₀: 4 nM	cdk2-cyclin E, IC₅₀: 35 nM cdk2-cyclin A, IC₅₀: 70 nM		cdk4-cyclin D1, IC₅₀: 850 nM	cdk5-p35, IC₅₀: 75 nM													99.11%
CLK1-IN-1																	CLK1, IC₅₀: 2 nM	99.05%
ON123300				Cdk4/cyclin D1, IC₅₀: 3.9 nM		CDK6/cyclinD1, IC₅₀: 9.82 nM												99.34%
Riviciclib hydrochloride	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM									98.33%
Cucurbitacin E	cyclin B1/CDC2																	99.92%
LDC000067	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM		cdk4-cyclin D1, IC₅₀: 9242 nM					CDK9- Cyclin T1, IC₅₀: 44 nM									98.58%
Abemaciclib metabolite M2				CDK4, IC₅₀: 1-3 nM		CDK6, IC₅₀: 1-3 nM												99.82%
Abemaciclib metabolite M20				CDK4		CDK6												98.24%
MSC2530818								CDK8, IC₅₀: 2.6 nM										99.69%
FMF-04-159-2		CDK2, IC₅₀: 256 nM (in NanoBRET assay)											CDK14/Cyclin Y, IC₅₀: 39.6 nM (in NanoBRET assay)					99.34%
CP-10						CDK6, DC₅₀: 2.1 nM												98.03%
Bisindolylmaleimide X hydrochloride		CDK2, IC₅₀: 200 nM																98.53%
ML167																	CLK4, IC₅₀: 136 nM CLK1, IC₅₀: 1522 nM CLK2, IC₅₀: 1648 nM	98.62%
LY2857785							CDK7, IC₅₀: 0.246 μM	CDK8, IC₅₀: 0.016 μM	CDK9, IC₅₀: 0.011 μM									98.88%
CDK5 inhibitor 20-223		CDK2, IC₅₀: 6.0 nM			CDK5, IC₅₀: 8.8 nM													99.64%
PF 477736	CDK1, Ki: 9.9 μM																	99.21%
BS-181 hydrochloride	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM									≥99.0%
CDK12-IN-E9		cdk2/cyclin A, IC₅₀: 932 nM					CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM		CDK9/cyclinT1, IC₅₀: 23.9 nM									99.20%
CDK9-IN-2									CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)									99.84%
Purvalanol B	cdc2/cyclin B, IC₅₀: 6 nM	cdk2/cyclin A, IC₅₀: 6 nM CDK2/cyclinE, IC₅₀: 9 nM			CDK5/p35, IC₅₀: 6 nM													≥97.0%
CDK9-IN-1									CDK9/CycT1, IC₅₀: 39 nM									98.52％
PROTAC CDK9 Degrader-1									CDK9									98.34%
BSJ-03-204				CDK4/D1, IC₅₀: 26.9 nM		CDK6/D1, IC₅₀: 10.4 nM												98.34%
CDKI-73	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM		CDK4, IC₅₀: 8.18 nM		CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM		CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM									99.58%
SU9516	CDK1, IC₅₀: 40 nM	CDK2, IC₅₀: 22 nM		CDK4, IC₅₀: 200 nM														99.83%
CC-671																	CLK2, IC₅₀: 0.006 μM	99.08%
CKI-7 free base																Cdc7		99.31%
AS2863619 free base								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM			≥98.0%
CDK-IN-2									CDK9/cyclinT1, IC₅₀: 8 nM									98.82%
YKL-5-124		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM									98.03%
ON-013100				Cdk4/cyclin D1														98.23%
Atuveciclib Racemate									CDK9									≥98.0%
TL12-186		cdk2/cyclin A, IC₅₀: 73 nM							CDK9/cyclinT1, IC₅₀: 55 nM									≥99.0%
Longdaysin							CDK7, IC₅₀: 29 μM											99.92%
AT7519 Hydrochloride	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM									99.29%
JH-XI-10-02								CDK8, IC₅₀: 159 nM										98.18%
BSJ-04-132				CDK4/D1, IC₅₀: 50.6 nM		CDK6/D1, IC₅₀: 30 nM												98.08%
(-)-BAY-1251152									CDK9									99.81%
AMG 925	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM												98.24%
PROTAC CDK2/9 Degrader-1		CDK2, DC₅₀: 62 nM							CDK9, DC₅₀: 33 nM									99.85%
Voruciclib	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM									99.52%
NU6102	Cdk1/cyclin B, IC₅₀: 9.5 nM	CDK2/cyclin A3, IC₅₀: 5.4 nM		CDK4, IC₅₀: 1.6 μM														≥95.0%
hSMG-1 inhibitor 11j	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																99.81%
Voruciclib hydrochloride	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM									98.20%
(R)-CR8	Cdk1/cyclin B, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM									≥98.0%
Lerociclib dihydrochloride	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM									99.74%
K00546	Cdk1/cyclin B, IC₅₀: 0.6 nM	cdk2/cyclin A, IC₅₀: 0.5 nM															CLK1, IC₅₀: 8.9 nM CLK3, IC₅₀: 29.2 nM	98.78%
LSN3106729 hydrochloride				CDK4		CDK6												99.01%
LY3177833																Cdc7, IC₅₀: 3.3 nM		99.76%
CDK9-IN-7				CDK4/cyclin D, IC₅₀: 148 nM		CDK6/cyclinD, IC₅₀: 145 nM			CDK9/cyclinT1, IC₅₀: 11 nM									99.81%
CDK9-IN-8									CDK9, IC₅₀: 12 nM									99.06%
NU6140	CDK1-Cyclin B, IC₅₀: 6.6 μM	cdk2-cyclin A, IC₅₀: 0.41 μM		CDK4-Cyclin D, IC₅₀: 5.5 μM	cdk5-p25, IC₅₀: 15 μM		cdk7-cyclin H, IC₅₀: 3.9 μM											≥99.0%
SY-5609		CDK2, Ki: 390 nM					CDK7, Kd: 0.059 nM		CDK9, Ki: 290 nM		CDK12, Ki: 78 nM							99.66%
BS-181	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM									98.10%
Olomoucine		cdk2-cyclin A, IC₅₀: 7 μM cdk2-cyclin E, IC₅₀: 7 μM																≥98.0%
BGG463		CDK2																≥98.0%
PNU112455A hydrochloride		CDK2, Km: 3.6 μM			CDK5, Km: 3.2 μM													99.62%
Garcinone C							CDK7											≥95.0%
Ribociclib succinate hydrate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM												99.96%
MC180295	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	CDK4-Cyclin D, IC₅₀: 112 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM		CDK9- Cyclin T1, IC₅₀: 5 nM									98.41%
CDK7-IN-1							CDK7, IC₅₀: 100 nM											98.91%
Palbociclib D8				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM												99.84%
BRD6989								CDK8, IC₅₀: ~200 nM recombinant CDK8, IC₅₀: ~0.5 μM							recombinant CDK19, IC₅₀: >30 μM			99.85%
Nimbolide				CDK4		CDK6												≥97.0%
NVP-LCQ195	Cdk1/cyclin B, IC₅₀: 2 nM	cdk2/cyclin A, IC₅₀: 2 nM CDK2/cyclinE, IC₅₀: 5 nM	CDK3/Cyclin E, IC₅₀: 42 nM		Cdk5/p25, IC₅₀: 1 nM CDK5/p35, IC₅₀: 1 nM	cdk6/cyclin D3, IC₅₀: 187 nM	CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM		CDK9/cyclinT1, IC₅₀: 15 nM									99.80%
JSH-150	Cdk1/cyclin B, IC₅₀: 1.34 μM	cdk2/cyclin A, IC₅₀: 2.86 μM			Cdk5/p25, IC₅₀: 4.64 μM		CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM		CDK9/cyclinT1, IC₅₀: 1 nM				CDK14/Cyclin Y, IC₅₀: 1.68 μM	CDK16/Cyclin Y, IC₅₀: 292 nM				98.36%
SEL120-34A HCl								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM			99.98%
EHT 5372																	CLK1, IC₅₀: 22.8 nM CLK2, IC₅₀: 88.8 nM CLK4, IC₅₀: 59.0 nM
Casein Kinase inhibitor A51							CDK7, Kd: 1.3 nM		CDK9, Kd: 4 nM									98.42%
IV-361		CDK2, Ki: ≥1000 nM					CDK7, Ki: ≤50 nM
XY028-133				CDK4		CDK6												98.03%
Samuraciclib trihydrochloride	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 31 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM									99.08%
NU6027	CDK1, Ki: 2.5 μM	CDK2, Ki: 1.3 μM																99.35%
Desmethylglycitein	CDK1	CDK2																≥95.0%
NU2058	CDK1, IC₅₀: 26 μM	CDK2, IC₅₀: 17 μM CDK2, Ki: 12 μM																99.01%
CDK8-IN-1								CDK8, IC₅₀: 3 nM										98.62%
CAN508	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM		Cdk4/cyclin D1, IC₅₀: 13.5 μM			CDK7/cyclin H, IC₅₀: 26 μM		CDK9/cyclinT1, IC₅₀: 0.35 μM									99.91%
CDK4/6-IN-2				CDK4, IC₅₀: 2.7 nM		CDK6, IC₅₀: 16 nM												99.82%
Alsterpaullone	Cdk1/cyclin B, IC₅₀: 35 nM	cdk2/cyclin A, IC₅₀: 15 nM CDK2/Cyc E, IC₅₀: 200 nM			CDK5/p35, IC₅₀: 40 nM													≥98.0%
FIT-039									CDK9/cyclinT1, IC₅₀: 5.8 μM									≥98.0%
TC11	CDK1																	98.04%
AMG 925 HCl	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM												98.01%
5-Iodo-indirubin-3'-monoxime	Cdk1/cyclin B, IC₅₀: 25 nM				Cdk5/p25, IC₅₀: 20 nM													99.50%
SEL120-34A								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM
XL413																Cdc7, IC₅₀: 3.4 nM
AT7519 TFA	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM									98.16%
PHA-767491	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM
Samuraciclib	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM
CDK4/6-IN-3	CDK1, Ki: 110 nM			CDK4, Ki: 0.3 nM		CDK6, Ki: 2.2 nM
FN-1501-propionic acid		CDK2							CDK9
CDK8/19-IN-1								CDK8/CycC, IC₅₀: 0.46 nM	CDK9, IC₅₀: 270 nM						CDK19/CycC, IC₅₀: 0.99 nM
CDK9-IN-9		CDK2, IC₅₀: 155 nM							CDK9, IC₅₀: 1.8 nM
CPS2		CDK2, IC₅₀: 24 nM
IIIM-290		CDK2/A, IC₅₀: 90 nM							CDK9/T1, IC₅₀: 94 nM
CDK12-IN-2		CDK2, IC₅₀: >100 μM					CDK7, IC₅₀: >10 μM CDK7, IC₅₀: >10 μM		CDK9, IC₅₀: 16 μM		CDK12, IC₅₀: 52 nM
Ipivivint	CDK1, IC₅₀: 1.4 μM	CDK2, IC₅₀: 0.002 μM	CDK3, IC₅₀: 0.022 μM
Riviciclib	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM
OTS964										CDK11B, Kd: 40 nM
CDK6/9-IN-1						CDK6, IC₅₀: 40.5 nM			CDK9, IC₅₀: 39.5 nM
Avotaciclib	CDK1
Dalpiciclib				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM
Lerociclib	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM
CDK7-IN-2 hydrochloride hydrate							CDK7
BS-181 dihydrochloride		CDK2, IC₅₀: 880 nM			CDK5, IC₅₀: 3000 nM		CDK7, IC₅₀: 21 nM		CDK9, IC₅₀: 4200 nM
CKI-7																Cdc7
Aloisine A	CDK1/cyclinB, IC₅₀: 0.15 μM	CDK2/cyclinA, IC₅₀: 0.12 μM CDK2/cyclinE, IC₅₀: 0.4 μM			CDK5/p35, IC₅₀: 0.16 μM
CDK9-IN-11									CDK9
Bohemine		CDK2/cyclinE, IC₅₀: 4.6 μM cdk2/cyclin A, IC₅₀: 83 μM							CDK9/cyclinT1, IC₅₀: 2.7 μM									≥98.0%
PROTAC CDK9 degrader-2									CDK9, IC₅₀: 17 μM (MCF-7 cells)
CDK4/6-IN-6				Cdk4/cyclin D1, Ki: 0.6 nM		cdk6/cyclin D3, Ki: 13.9 nM
CDK12-IN-5		CDK2/cyclinE, IC₅₀: 173 μM							CDK9/cyclinT1, IC₅₀: 127 μM		CDK12, IC₅₀: 23.9 nM
NSC 625987				CDK4/D1, IC₅₀: 0.2 μM
CDK5-IN-1					CDK5
CDK12-IN-6		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 1.19 μM
Cdk1/2 Inhibitor III	Cdk1/cyclin B, IC₅₀: 2.1 μM
3-Methylthienyl-carbonyl-JNJ-7706621	CDK1/cyclinB, IC₅₀: 6.4 nM	CDK2/cyclinA, IC₅₀: 2 nM		CDK4, IC₅₀: 0.11 μM
CDK12-IN-4		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 0.641 μM
Casein Kinase inhibitor A86							CDK7, Kd: 0.31 nM		CDK9, Kd: 5.4 nM
Indirubin-3'-monoxime-5-sulphonic acid	CDK1, IC₅₀: 5 nM				CDK5, IC₅₀: 7 nM
Indirubin-5-sulfonate	Cdk1/cyclin B, IC₅₀: 55 nM	cdk2/cyclin A, IC₅₀: 35 nM CDK2/cyclinE, IC₅₀: 150 nM		Cdk4/cyclin D1, IC₅₀: 300 nM	CDK5/p35, IC₅₀: 65 nM
CDK9-IN-10									CDK9
hSMG-1 inhibitor 11e	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																99.18%

Name
Email *

	Sorry, but the email address you supplied was invalid.